Open
Do DPP-4 inhibitors improve kidney outcomes more than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 1
- Inconclusive
- 0
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 46
- With posted results
- 13
- Published papers
- 0
Of 2 decided analyses: 0 favor dpp-4 inhibitors, 2 find no difference, 0 favor the comparator.
Trials
- Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With DPP-4 InhibitorsNCT02864914 · 6 posted results
- A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference ArmNCT00642278 · 6 posted results
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?NCT02879409
- Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.NCT04735042
- Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled TrialNCT06098625
- Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial (EmLina Renal Trial)NCT06095492
- Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes MellitusNCT05359432
- A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenNCT02077946